JP5377503B2 - 置換されたｎ−フェニル−ビピロリジンカルボキサミド及びその治療上の使用 - Google Patents

置換されたｎ−フェニル−ビピロリジンカルボキサミド及びその治療上の使用 Download PDF

Info

Publication number
JP5377503B2
JP5377503B2 JP2010530049A JP2010530049A JP5377503B2 JP 5377503 B2 JP5377503 B2 JP 5377503B2 JP 2010530049 A JP2010530049 A JP 2010530049A JP 2010530049 A JP2010530049 A JP 2010530049A JP 5377503 B2 JP5377503 B2 JP 5377503B2
Authority
JP
Japan
Prior art keywords
methyl
bipyrrolidinyl
phenyl
amide
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010530049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500693A5 (enExample
JP2011500693A (ja
Inventor
ヴェルンガルト・チェヒティツキ
チョンリー・ガオ
ウィリアム・ジェイ・ハースト
ロータール・シュヴィンク
ジークフリート・シュテンゲリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2011500693A publication Critical patent/JP2011500693A/ja
Publication of JP2011500693A5 publication Critical patent/JP2011500693A5/ja
Application granted granted Critical
Publication of JP5377503B2 publication Critical patent/JP5377503B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2010530049A 2007-10-17 2008-10-14 置換されたｎ−フェニル−ビピロリジンカルボキサミド及びその治療上の使用 Expired - Fee Related JP5377503B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98059907P 2007-10-17 2007-10-17
US60/980,599 2007-10-17
PCT/US2008/079757 WO2009052062A1 (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Publications (3)

Publication Number Publication Date
JP2011500693A JP2011500693A (ja) 2011-01-06
JP2011500693A5 JP2011500693A5 (enExample) 2011-12-01
JP5377503B2 true JP5377503B2 (ja) 2013-12-25

Family

ID=40247942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530049A Expired - Fee Related JP5377503B2 (ja) 2007-10-17 2008-10-14 置換されたｎ−フェニル−ビピロリジンカルボキサミド及びその治療上の使用

Country Status (25)

Country Link
US (2) US8088808B2 (enExample)
EP (1) EP2212283B1 (enExample)
JP (1) JP5377503B2 (enExample)
KR (1) KR20100072077A (enExample)
CN (1) CN101903340B (enExample)
AT (1) ATE525351T1 (enExample)
AU (1) AU2008312635B2 (enExample)
BR (1) BRPI0818581A2 (enExample)
CA (1) CA2702467C (enExample)
CY (1) CY1112083T1 (enExample)
DK (1) DK2212283T3 (enExample)
ES (1) ES2372332T3 (enExample)
HR (1) HRP20110762T1 (enExample)
IL (1) IL205001A (enExample)
MA (1) MA31858B1 (enExample)
MX (1) MX2010003949A (enExample)
MY (1) MY151348A (enExample)
NZ (1) NZ584690A (enExample)
PL (1) PL2212283T3 (enExample)
PT (1) PT2212283E (enExample)
RS (1) RS52235B (enExample)
RU (1) RU2477720C2 (enExample)
SI (1) SI2212283T1 (enExample)
WO (1) WO2009052062A1 (enExample)
ZA (1) ZA201002115B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100092443A (ko) 2007-10-17 2010-08-20 사노피-아벤티스 치환된 ｎ-페닐-피롤리디닐메틸피롤리딘 아미드 및 히스타민 ｈ3 수용체 조절제로서의 이의 치료적 용도
PL2215058T3 (pl) 2007-10-17 2012-04-30 Sanofi Sa Podstawione N-fenylo-bipirolidynomoczniki oraz ich zastosowanie terapeutyczne
DK2212282T3 (da) 2007-10-17 2012-01-23 Sanofi Sa Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
BRPI0818581A2 (pt) * 2007-10-17 2015-07-21 Sanofi Aventis Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas
AR074467A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
WO2011143145A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
AR081384A1 (es) * 2010-05-11 2012-08-29 Sanofi Aventis N- fenil espirolactama bipirrolidinas sustituidas, preparacion y uso terapeutico de las mismas
JP5968307B2 (ja) 2010-05-11 2016-08-10 サノフイ 置換フェニルシクロアルキルピロリジン（ピペリジン）スピロラクタム類及びアミド類、それらの製造及び治療的使用
JP2013529198A (ja) 2010-05-11 2013-07-18 サノフイ 置換されたｎ−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用
TW201202251A (en) * 2010-05-11 2012-01-16 Sanofi Aventis Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
JP2013526529A (ja) * 2010-05-11 2013-06-24 サノフイ 置換されたｎ−ヘテロアリールビピロリジンカルボキサミド、その製造及び治療上の使用
JP5784110B2 (ja) 2010-05-11 2015-09-24 サノフイ 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用
ES2527466T3 (es) 2010-07-06 2015-01-26 Astrazeneca Ab Agentes terapéuticos 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
JP2013232564A (ja) * 2012-04-27 2013-11-14 National Institute Of Advanced Industrial & Technology 半導体装置および半導体装置の製造方法
CN103694163A (zh) * 2012-09-27 2014-04-02 上海先声药物研究有限公司 作为钾通道调节剂的化合物
CN104884058A (zh) 2013-01-10 2015-09-02 格吕伦塔尔有限公司 作为crac通道抑制剂的基于吡唑基的甲酰胺ii
US9206136B2 (en) 2013-01-10 2015-12-08 Grünenthal GmbH Pyrazolyl-based carboxamides I
EP3366683A1 (en) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
WO2004037257A1 (en) * 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT1861360E (pt) 2005-03-17 2010-01-28 Lilly Co Eli Derivados de pirrolidina como antagonistas de receptores h3 de histamina
CN101151244B (zh) * 2005-04-01 2014-09-03 伊莱利利公司 组胺h3受体活性剂、制备和治疗用途
ATE523488T1 (de) * 2005-07-01 2011-09-15 Lilly Co Eli Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung
CA2627234A1 (en) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
AU2007214709A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
BRPI0818581A2 (pt) * 2007-10-17 2015-07-21 Sanofi Aventis Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas
DK2212282T3 (da) 2007-10-17 2012-01-23 Sanofi Sa Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
PL2215058T3 (pl) 2007-10-17 2012-04-30 Sanofi Sa Podstawione N-fenylo-bipirolidynomoczniki oraz ich zastosowanie terapeutyczne
KR20100092443A (ko) 2007-10-17 2010-08-20 사노피-아벤티스 치환된 ｎ-페닐-피롤리디닐메틸피롤리딘 아미드 및 히스타민 ｈ3 수용체 조절제로서의 이의 치료적 용도

Also Published As

Publication number Publication date
WO2009052062A1 (en) 2009-04-23
CN101903340A (zh) 2010-12-01
HK1146053A1 (en) 2011-05-13
EP2212283B1 (en) 2011-09-21
EP2212283A1 (en) 2010-08-04
ES2372332T3 (es) 2012-01-18
PL2212283T3 (pl) 2012-01-31
NZ584690A (en) 2011-09-30
US20100173949A1 (en) 2010-07-08
US20120065234A1 (en) 2012-03-15
PT2212283E (pt) 2011-11-03
RU2477720C2 (ru) 2013-03-20
US8088808B2 (en) 2012-01-03
MA31858B1 (fr) 2010-11-01
JP2011500693A (ja) 2011-01-06
DK2212283T3 (da) 2011-12-19
MY151348A (en) 2014-05-15
SI2212283T1 (sl) 2011-12-30
CN101903340B (zh) 2013-03-27
KR20100072077A (ko) 2010-06-29
RS52235B (sr) 2012-10-31
HRP20110762T1 (hr) 2011-11-30
US8252824B2 (en) 2012-08-28
AU2008312635A1 (en) 2009-04-23
RU2010119528A (ru) 2011-11-27
CY1112083T1 (el) 2015-11-04
MX2010003949A (es) 2010-04-30
CA2702467A1 (en) 2009-04-23
AU2008312635B2 (en) 2013-05-16
CA2702467C (en) 2012-11-27
BRPI0818581A2 (pt) 2015-07-21
IL205001A (en) 2014-06-30
ATE525351T1 (de) 2011-10-15
ZA201002115B (en) 2010-12-29
IL205001A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
JP5377503B2 (ja) 置換されたｎ−フェニル−ビピロリジンカルボキサミド及びその治療上の使用
JP5255644B2 (ja) 置換されたｎ−フェニル−ビピロリジンカルボキサミド及びその治療上の使用
JP5380455B2 (ja) 置換されたｎ−フェニル−ビピロリジン尿素及びその治療上の使用
JP5377504B2 (ja) 置換されたｎ−フェニル−ピロリジニルメチルピロリジンアミドおよびその治療的用途
JP5410544B2 (ja) 置換されたテトラヒドロピランスピロピロリジノン及びピペリジノン、それらの製造及び治療上の使用
US8871788B2 (en) Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
JP2013529198A (ja) 置換されたｎ−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用
EP2569294B1 (en) Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
HK1146053B (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
HK1146054B (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130924

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees